A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Recruiting

Phase 3

Pozelimab & CemdisiranA Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT06541704

Conditions

Age-related Macular Degeneration (AMD)

Geographic Atrophy (GA)

Eligibility Criteria

Sex: All

Age: 50+

Healthy Volunteers: Not accepted

Interventions

Pozelimab

Cemdisiran

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-04-27. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2025-04-23.